Phase 2 Study to Assess the Safety and Efficacy of ANG003

Summary

In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.

Timeline

Start

2026-04-24

Primary completion

2027-07

Completion

2027-07

Drugs

Indications